

## Cocrystal Pharma to Appoint Jeffrey Meckler as Interim Chief Executive Officer

BOTHELL, WA and ATLANTA, GA -- (Marketwired) -- 03/12/15 -- Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that due to medical reasons, Dr. Gary Wilcox will step down as the current Chief Executive Officer. Mr. Jeffrey Meckler has been appointed as the Interim Chief Executive Officer of the Company effective with the filing of the Form 10-K, later this month. Dr. Wilcox will become the Vice Chairman of the Board of Directors and continue as a senior advisor to the company. Mr. Meckler will continue as a Director of the Company, and Dr. Raymond F. Schinazi will become the Chairman of the Board.

Mr. Meckler has over 25 years of experience in life science companies including 17 years at Pfizer Inc. in a variety of positions, including Manufacturing, Systems, Market Research and Corporate Finance. Mr. Meckler most recently was the Principal Executive Officer of QLT Inc., an ophthalmic orphan drug company located in Vancouver, British Columbia.

## About Cocrystal Pharma

Cocrystal is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. The company has identified promising, preclinical stage compounds for hepatitis infections, and analogs that are effective against noroviruses. Cocrystal has previously received strategic investments from Teva Pharmaceuticals, OPKO Health (NYSE: OPK), Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group. For further information about Cocrystal, please refer to <a href="https://www.cocrystalpharma.com">www.cocrystalpharma.com</a>.

Contact:MDM Worldwide David Zazoff 212-643-0417

Source: Cocrystal Pharma, Inc.